Benitec Biopharma Inc./$BNTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Ticker
$BNTC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
16
ISIN
US08205P2092
Website
BNTC Metrics
BasicAdvanced
$354M
-
-$1.47
0.34
-
Price and volume
Market cap
$354M
Beta
0.34
52-week high
$17.15
52-week low
$10.50
Average daily volume
170K
Financial strength
Current ratio
14.804
Quick ratio
14.743
Long term debt to equity
0.628
Total debt to equity
0.983
Profitability
EBITDA (TTM)
-30.059
Management effectiveness
Return on assets (TTM)
-31.34%
Return on equity (TTM)
-48.57%
Valuation
Price to book
3.53
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
-13.047
Free cash flow yield (TTM)
-7.66%
Free cash flow per share (TTM)
-103.39%
Growth
Earnings per share change (TTM)
-19.07%
3-year earnings per share growth (CAGR)
-65.89%
10-year earnings per share growth (CAGR)
-39.66%
Bulls say / Bears say
Benitec Biopharma reported positive interim clinical results for three subjects treated with BB-301 in its Phase 1b/2a study, indicating potential efficacy in treating Oculopharyngeal Muscular Dystrophy (OPMD). (benitec.com)
The company successfully raised $30 million through a common stock offering in March 2025, bolstering its financial position to support ongoing research and development. (benitec.com)
As of March 31, 2025, Benitec Biopharma had $103.6 million in cash and cash equivalents, providing a solid financial foundation for future operations. (benitec.com)
For the quarter ended March 31, 2025, Benitec Biopharma reported a net loss of $9.4 million, indicating ongoing financial challenges. (benitec.com)
The company's research and development expenses increased to $6.0 million for the quarter ended March 31, 2025, up from $2.6 million in the same period the previous year, reflecting higher operational costs. (benitec.com)
General and administrative expenses rose to $4.2 million for the quarter ended March 31, 2025, compared to $1.6 million in the same quarter of 2024, potentially impacting profitability. (benitec.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Benitec Biopharma Inc. stock?
Benitec Biopharma Inc. (BNTC) has a market cap of $354M as of July 08, 2025.
What is the P/E ratio for Benitec Biopharma Inc. stock?
The price to earnings (P/E) ratio for Benitec Biopharma Inc. (BNTC) stock is 0 as of July 08, 2025.
Does Benitec Biopharma Inc. stock pay dividends?
No, Benitec Biopharma Inc. (BNTC) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Benitec Biopharma Inc. dividend payment date?
Benitec Biopharma Inc. (BNTC) stock does not pay dividends to its shareholders.
What is the beta indicator for Benitec Biopharma Inc.?
Benitec Biopharma Inc. (BNTC) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.